Roche's experimental lung cancer drug beat two rivals in a pivotal trial Oct 26, 2026 · Cris Tolomia Median overall survival reached 17.7 months with divarasib versus 12.0 months for sotorasib or adagrasib in a 338-patient phase III study Read more »